🇺🇸 FDA
Pipeline program

DS-8201a

ROMast-001

Phase 3 small_molecule active

Quick answer

DS-8201a for Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors is a Phase 3 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Daiichi Sankyo Europe GmbH
Indication
Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials